



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

April 13, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code - INFLUX

Dear Sir/Ma'am,

Sub: Press Release – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We are enclosing herewith the Press Release dated April 13, 2026 titled, **“Investor Clarification – Variation in Objects of IPO Proceeds”**.

We request you to take the above information on record.

Thanking you,

Yours Faithfully,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

INVESTOR CLARIFICATION – VARIATION IN OBJECTS OF IPO PROCEEDS

[Pursuant to Section 27 of the Companies Act, 2013, Regulation 32 of SEBI (LODR) Regulations, 2015, and SEBI (ICDR) Regulations, 2018, read with Postal Ballot Notice dated April 1, 2026.]

Mumbai, April 13, 2026: Influx Healthtech Limited (CIN: U24299MH2020PLC346825) hereby informs its Members, investors, regulators, and the general public of a proposed variation in the utilisation of IPO proceeds, as detailed in the Postal Ballot Notice dated April 1, 2026 and Corrigendum dated April 6, 2026. This communication is issued in the interest of full transparency and investor protection.

IPO Background & Utilisation Status (as on March 31, 2026):

The Company raised **₹4,800.38 Lakhs** through a Fresh Issue IPO in Financial Year 2024–2025, via Prospectus dated June 23, 2025. Original objects and utilisation status as on March 31, 2026:

(₹ Lakhs)

Object / Particulars	Allocation	Utilised till 31.03.2026	Achievement (%)	Unutilised
Nutraceutical Division – Manufacturing Facility (Plot No. 59)	2,249.11	1,100.50	48.93%	1,148.61
Veterinary Food Division – Manufacturing Facility (Plot No. 28)	1,148.58	138.00	12.01%	1,010.58
Purchase of Machineries – Homecare & Cosmetic Division	275.65	74.96	27.19%	200.69
General Corporate Purposes (GCP)*	667.40	667.40	100.00%	0.00
TOTAL	4,340.74	1,980.86	45.63%	2,359.87

* GCP revised from ₹543.81 Lakhs to ₹667.40 Lakhs consequent to the Company bearing ₹123.59 Lakhs of IPO expenses on behalf of the Selling Shareholder, which were subsequently reimbursed and credited to GCP. Unutilised funds of ₹2,359.87 Lakhs are currently lying in bank balances pending utilisation.

Proposed Variation in IPO Proceeds:

The Board of Directors at its meeting held on March 31, 2026 approved the reallocation of **₹1,009.31 Lakhs** from surplus amounts across veterinary facility and machinery allocations towards the enhanced construction cost for Plot No. 59 (Nutraceutical CDMO Facility), subject to shareholder approval via Postal Ballot.

(₹ Lakhs)

Division / Head	As per Prospectus	Utilised till 31.03.26	Reallocated Out	Reallocated In
Nutraceutical Division – Plot No. 59*	2,249.11	1,100.50	393.36	1,796.37
Veterinary Food Division – Plot No. 28	1,148.58	138.00	549.35	–
Homecare & Cosmetic Division – Machinery	275.65	74.96	66.60	–
GRAND TOTAL	3,673.34	1,313.47	1,009.31	1,796.37

Note: Red figures denote outflows (reallocated from); green figures denote inflows (reallocated to)

*Reallocated ₹393.36 lakhs from plant & machinery to building & civil works of Plot No. 59.

Means of Finance – Revised Construction Cost of ₹1,796.37 Lakhs for Plot No. 59:

(₹ Lakhs)

Source of Funds	Amount
Original Allocation – Plot No. 59 (Building & Civil Works)	787.06
Reallocation from Plot No. 28 (Civil Works Surplus)	429.23
Reallocation from Machinery Allocations (Surplus across all three divisions)	580.08
TOTAL	1,796.37

RATIONALE FOR PROPOSED VARIATION

Plot No. 59 – Nutraceutical CDMO Facility:

The cost revision from ₹787.06 Lakhs to ₹1,796.37 Lakhs reflects a strategic scale-up, including expansion from Approx 35,000 to 75,000 sq. ft., addition of basement utilities, enhanced GMP-compliant design (WHO-GMP, FSSAI, 21 CFR), upgraded HVAC and material flow systems, and higher construction and compliance costs. This aligns with strong demand visibility and supports a scalable, future-ready nutraceutical CDMO platform.

Plot No. 28 – Veterinary Food Division:

The revision from ₹679.23 Lakhs to ₹250.00 Lakhs reflects a phased, demand-aligned approach with no dilution in commitment. Initial construction focuses on core capacity with modular expansion planned, while design optimisation and vendor negotiations reduce upfront costs. Planned machinery capacity remains unchanged.

Machinery Allocation Surplus:

Vendor negotiations resulted in a machinery surplus of ₹580.08 Lakhs across divisions (add those divisions). Some procurement has been phased with production ramp-up. For post-construction works at Plot No. 59 and 28, the company may engage additional vendors based on cost, quality, and efficiency, without altering the IPO's objectives.

Categorical Confirmations:

- No IPO proceeds are being diverted towards working capital, general corporate purposes, or any purpose unrelated to the original capital expenditure objectives.
- The reallocation remains strictly within the scope of capital expenditure for long-term growth, entirely within the ambit of the originally stated objects.
- Funds proposed for reallocation are presently lying in bank balances pending utilisation.
- The variation does not result in any change in the Company's overall capital structure.
- No Director, Key Managerial Personnel, or their relatives are concerned or interested in the proposed resolution, except to the extent of their respective shareholding in the Company.

Financial Impact:

- The proposed variation is not expected to have any adverse impact on the earnings or cash flows of the Company.
- No additional external borrowings or interest costs will be incurred; the reallocation utilises surplus funds already available under originally stated objects.
- Enhanced construction of Plot No. 59 is expected to strengthen the Company's operational capacity and revenue-generating potential in the medium-to-long term.
- Deferred machinery purchases will be funded via internal accruals and are not expected to materially impact ongoing operations.
- The proposed enhanced construction on Plot No. 59 is expected to be completed within approximately **180 days** from the date of approval by Members.

Voluntary 90% Shareholder Approval Threshold:

As a voluntary governance measure, the Board has resolved that the proposed variation shall be implemented only if approved by **Members holding more than 90% of total shareholding** (present and voting, including remote e-voting), as against the **statutory minimum of 75% for a special resolution**. The Board clarifies that since this voluntary 90% threshold is being applied, the provisions of **Regulation 59 read with Schedule XX of the SEBI (ICDR) Regulations, 2018** relating to the exit offer by the promoter do not apply to this proposed resolution. **Members are requested to review the Postal Ballot Notice dated April 1, 2026 in its entirety for details regarding the e-voting process.**

Risk Factors:

Members are drawn to the following risk factors pertaining to the revised objects: potential escalation in construction costs due to inflationary pressures; possible delays from regulatory approvals or supply chain disruptions; temporary impact on production scalability due to deferred machinery procurement; and fluctuations in market demand affecting projected returns from expanded capacity. The Board believes the revised allocation is commercially prudent and in the best interest of the Company.

The above information is being provided in compliance with applicable SEBI regulations. The Company will continue to keep the stock exchanges informed of all material developments.

We request you to take the above information on record.

Thanking you,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Chairman and Managing Director
DIN: 08459582

Date: April 13, 2026 | Place: Mumbai

Disclaimer: This Press Release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially. This release is issued in compliance with applicable SEBI regulations and is intended solely for investor information and transparency. It does not constitute an offer to buy or sell securities. Members are advised to read the full Postal Ballot Notice dated April 1, 2026 and Corrigendum dated April 6, 2026 before exercising their vote.



Company
Influx Healthtech Limited
Ashish Shah
Chief Financial Officer
cs@influxhealthtech.com

Investor Relations Consultants

Capital Bridge Advisory Service Private Limited

info@capbridge.in
079-4918 4116